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Abstract
Objective To evaluate the efficacy and safety of two dose
levels of galsulfase (Naglazyme®) in infants with MPS VI.
Study design This was a phase 4, multicenter, multinational,
open-label, two-dose level study. Subjects were randomized
1:1 to receive weekly infusions of 1.0 or 2.0 mg/kg of
galsulfase for a minimum of 52 weeks. Progression of skeletal
dysplasia was determined by monitoring physical appearance,
radiographic changes, and growth. Urinary glycosaminogly-
can (GAG) levels, gross and fine motor function, cardiac
function, vision, hearing, and health resource utilization were
evaluated. Safety assessments were performed.
Results Four infants (aged 3.3–12.7 months) participated in the
study. Galsulfase was well tolerated at 1.0 and 2.0 mg/kg/week
dose levels with no drug-related serious adverse events. Two
subjects experienced a total of four possible treatment-related
adverse events which were all considered mild. Length and
weight remained within age-expected norms. Skeletal abnor-
malities continued to progress in all subjects. High baseline
urinary GAG levels (mean: 870μg/mg creatinine) decreased by
approximately 70 %; these reduced levels were maintained
(mean: 220 μg/mg creatinine at week 52) despite the develop-
ment of anti-galsulfase antibodies. Hearing, cardiac function,
hepatosplenomegaly, and facial dysmorphism stabilized or im-
proved, but corneal clouding progressed. There was no clear
difference in safety or efficacy between the two doses.
Conclusions Galsulfase at two dose levels was safe and well
tolerated in infants. Normal growth was maintained but skel-
etal abnormalities continued to progress. Urinary GAG levels
decreased with treatment. Early initiation of galsulfase may
prevent or slow progression of some disease manifestations.
Introduction
Mucopolysaccharidosis VI (MPS VI, or Maroteaux-Lamy
syndrome; OMIM 253200) is a lysosomal storage disorder
caused by deficient activity of N -acetylgalactosamine 4-
sulfatase (arylsulfatase B or ASB; EC 3.1.6.12), the enzyme
that catabolizes the glycosaminoglycan (GAG) dermatan sul-
fate. Affected individuals usually appear normal at birth, but
intracellular GAG accumulation leads to progressive develop-
ment of multisystemic clinical manifestations, including short
stature, skeletal abnormalities, respiratory complications, car-
diac disease, corneal clouding, hearing loss, spinal cord com-
pression and reduced physical endurance (Giugliani et al
2007; Valayannopoulos et al 2010). Patients typically present
with the radiographic changes of dysostosis multiplex, which
comprise malformations of the skull, thorax, spine, pelvis, long
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bones and hands (Lachman et al 2010). There is wide variability
in phenotypic presentation. Rapidly progressing patients usually
begin to show symptoms shortly after birth and are typically
diagnosed between 2 and 4 years of age (unless they have a
family history). Most do not live to adulthood. Individuals with a
slower disease course typically develop similar symptoms later in
life (Thumler et al 2012). Urinary GAG levels >200 μg/mg
creatinine are generally associated with rapidly progressive dis-
ease while urinary GAG levels <100 μg/mg creatinine are
associated with a slowly progressing clinical course and longer
survival (Swiedler et al 2005).
Galsulfase (Naglazyme®), a recombinant human N–
acetylgalactosamine 4–sulfatase (rh-arylsulfatase B; rhASB),
is currently approved by the United States Food and Drug
Administration (US FDA), the European Medicines Agency
(EMA) and regulatory agencies in several other countries as
first-line therapy for MPS VI at an intravenous (IV) infusion
dose of 1.0 mg/kg/week. Treatment with this dose of galsulfase
has been shown to improve walking and stair-climbing capacity
(Harmatz et al 2005). Enzyme replacement therapy (ERT) with
galsulfase has also resulted in improvements in pulmonary
function (Harmatz et al 2005, 2008), growth rate (Decker et al
2010), and pubertal development (Decker et al 2010). Approval
of galsulfase as treatment for MPS VI was based on improve-
ment in endurance in patients older than 5 years of age. Studies
of two MPS VI sibling pairs, one from Australia (McGill et al
2010) and one from Japan (Furujo et al 2011), as well as a
recent report from Brazil of 34 MPS VI children younger than
5 years (Horovitz et al 2013), suggest that initiation of ERT at
an earlier age facilitates better outcomes, underscoring the need
to evaluate the use of galsulfase in infants and very young
children in controlled trials. Moreover, early intervention may
have the potential to normalize bone growth and reduce the
significant morbidity caused by skeletal involvement. Although
results from both sibling studies suggest that early ERT at the
1 mg/kg/week dose does not prevent the progression of skeletal
pathology in MPS VI infants and children under 5 years of age
(Furujo et al 2011; McGill et al 2010), the effect of a higher
dose of galsulfase has not been investigated. In MPS VI-
affected cats, improvements in bone development as well as
other MPS VI disease symptoms were associated with higher
enzyme doses when ERT was initiated from birth (Byers et al
1997; Crawley et al 1997). Administration of a weekly 2 mg/kg
dose would represent a significant increase in drug exposure as
well as enable evaluation of safety of a higher dose.
The primary objective of this study was to evaluate the
efficacy of two dose levels (1.0 and 2.0 mg/kg/week) of
galsulfase on the progression of skeletal dysplasia (as reflected
by changes in radiographs, physical appearance, and growth)
in infants with MPS VI. The secondary objective was to
evaluate efficacy based on urinary GAG levels and assess-
ments of gross and fine motor function, cardiac function,
vision, hearing, and health resource utilization. In addition,
the safety of ERT in infants was evaluated at these two dose
levels.We describe the efficacy and safety results of galsulfase
therapy administered in four infants for a minimum of
52 weeks.
Methods
Study design
This was a multicenter, multinational, open-label, random-
ized, two-dose level study conducted in accordance with
International Conference on Harmonization Good Clinical
Practice (ICH GCP) and the principles of the Declaration of
Helsinki. An institutional review board (IRB) or independent
ethics committee (IEC) at each study center approved the
study protocol, the subject informed consent form (ICF) and
all subject recruitment materials. Parents or legal guardian
signed an ICF prior to study enrollment and performance of
any study-specific procedures and assessments.
Subjects who met eligibility criteria or received protocol
exemptions at screening underwent baseline assessments over
a 2-week period and were randomized 1:1 to weekly, open-
label treatment with either 1.0 or 2.0 mg/kg of galsulfase
administered by IV infusion for a minimum of 52 weeks.
Subject selection
Subjects were initially required to be less than 1 year of age, to
be diagnosed with MPS VI (through documented prenatal
diagnosis or fibroblast or leukocyte ASB enzyme activity
level <10 % of the lower limit of the normal range) and to
have no evidence of skeletal dysplasia based on physical
examination. Protocol exemptions were granted by the spon-
sor to the investigative sites for two infants based on age
greater than 1 year (53 and 55 weeks) and for all subjects
based on presence of skeletal dysplasia. Due to the rarity of
MPS VI and difficulty in diagnosis before 2 to 3 years of age,
recruitment was challenging. After significant effort (>2 years)
to recruit patients, it was deemed that inclusion of patients
slightly over 1 year of age and with radiographic evidence of
skeletal dysplasia was sufficient and necessary to complete the
study. Two subjects (subjects 1 and 2) were identified and
evaluated for MPS VI based on known family history (older
sibling with diagnosed MPS). The other two subjects (subjects
3 and 4) were tested for MPS VI based on clinical symptoms.
Study drug administration
Subjects received weekly IV infusions of galsulfase. Two
subjects (subjects 1 and 4) received pre-medication with anti-
histamine from the time of initiation of study drug infusions.
Galsulfase doses were recalculated at monthly intervals based
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on the most recent weight obtained. Galsulfase solution was
diluted with sterile 0.9 % sodium chloride solution to 50 mL
for subjects weighing less than 5 kg, 100 mL for subjects
between 5 and 10 kg and 250 mL for subjects weighing at
least 10 kg. Infusion rates were adjusted so that approximately
2.5 % of the total solution was infused during the first hour
and the remaining volume (approximately 97.5 %) over a
minimum of an additional 3 h.
Primary efficacy assessments
Primary efficacy was assessed by changes in dysmorphic
features in physical examinations, radiographic changes, and
anthropometric growth measurements. Physical examinations
were performed by individual site investigators at screening
and follow-up visits, noting presence or absence of dysmor-
phic changes characteristic of MPS VI including, but not
limited to, coarse facies, joint contractures, bony abnormali-
ties of the spine and thorax, and claw hand deformity. Skeletal
surveys were performed at baseline and at 52 weeks after
initiation of study treatment. Radiographs were reviewed by
a pediatric radiologist (R.S. Lachman) with extensive experi-
ence evaluating radiographs for MPS pathologies. Growth
assessments, consisting of length, weight and head circumfer-
ence measurements (Kuczmarski et al 2002), were conducted
at baseline and throughout the duration of treatment for each
patient. Because subjects were enrolled over a period of >
2 years, growth data ranged from 52 weeks for the last subject
enrolled to 152 weeks for the first subject enrolled.
Secondary efficacy assessments
Urinary GAG levels were evaluated at baseline and through-
out the duration of treatment for each subject prior to infusions
using the Automated Quantitation of Total Sulfated
Glycosaminoglycans in Urine procedure with the GAGBotI
Analyzer (Whitley et al 1989). Gross and fine motor skills
were evaluated using the DENVER II Development Test
(Frankenburg et al 1992) in three subjects (subjects 1, 2 and
4) and by the Griffiths Scales (Ivens and Martin 2002) in one
subject (subject 3) at baseline and weeks 26 and 52.
Cardiac data were extracted from reports submitted by
participating sites. At each site, cardiac function was assessed
at baseline and at week 52 by transthoracic two-dimensional
echocardiography including color andDoppler interrogation of
cardiac valves. Measurements included left ventricular cham-
ber dimensions in systole and diastole, diastolic septal and
posterior wall thicknesses, and interrogation of cardiac valves
for the presence or absence of stenosis or regurgitation. Body
surface area-based Z-scores were calculated for chamber di-
mensions and wall thicknesses to allow comparison within the
same subject over time and between subjects of different body
surface areas (http://parameterz.blogspot.com/).
Complete ophthalmologic evaluations were conducted at
baseline and at week 52, and included intraocular pressure
(IOP) for glaucoma, examination of the retina and optic nerve,
and documentation of corneal clouding. Audiological testing by
audiometry was conducted at baseline and at week 52. Health
resource utilization at baseline and throughout the study was
queried through a questionnaire which documented the occur-
rence of physical therapy, hospitalizations, procedures
performed, outpatient visits, and emergency room (ER) visits.
Safety assessments
Safety was assessed throughout each infusion and for a
minimum of 1 h post-infusion, by physical examinations,
medical history, vital signs, concomitant medications (pre-
scription and over the counter), changes in laboratory pa-
rameters, anti-rhASB antibody testing and adverse events
(AEs). Total anti-rhASB antibody analysis was conducted
using a validated bridged immunoassay format based on
electrochemiluminescence (ECL) detection (BioMarin
Pharmaceutical Inc., Novato, CA, USA) and was performed
throughout the duration of treatment for each subject.
Statistical methods
Descriptive statistics were used to summarize the data in this
small number of subjects. Categorical variables were summa-
rized using frequencies, percentages, and shift from baseline.
Continuous variables were summarized by the number of
subjects, mean, median, standard deviations, minimum and
maximum values.
Results
Demographics
Four subjects enrolled and received a minimum of 52 weeks
of 1.0 or 2.0 mg/kg/week (two subjects per dose level)
galsulfase treatment. No subject withdrew from the study.
All subjects were male with a mean age at the time of enroll-
ment of 9.2 months (40 weeks). At baseline, subjects 1, 2, 3,
and 4 were aged 8.8, 3.3, 12.1 and 12.7 months, respectively.
The two oldest subjects were randomized to 2.0 mg/kg/week
galsulfase. The diagnosis of MPS VI disease was confirmed
upon enrollment (ASB enzyme activity in fibroblasts for 1
subject and leukocyte ASB enzyme activity in whole blood
for 3 subjects). Serum TSH and free T4 levels were assessed
as normal for all subjects. Urinary GAG levels at baseline
were high for all subjects, with an overall mean of 870 μg/mg
creatinine. Subjects 3 and 4 in the 2.0 mg/kg/week dose group
were administered all doses of scheduled galsulfase infusions.
Subjects 1 and 2 in the 1.0 mg/kg/week dose group each
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missed at least one galsulfase infusion (a total of four missed
infusions) within the first 52 weeks of treatment, resulting in a
compliance rate of 98 % over this time period. In total,
subjects received 392 of 396 scheduled doses over the course
of the study for an overall treatment compliance rate of 99 %.
Primary efficacy
Physical appearance
All subjects presented with some characteristic clinical fea-
tures of MPS VI at baseline and throughout the study period,
as shown in Table 1. Kyphosis (subjects 1, 3 and 4), and chest
wall deformities (pectus carinatum in subjects 1 and 3, and
pectus excavatum in subject 4) were the most commonly
reported findings at baseline. Facial dysmorphism improved
in subject 3 and did not worsen in subject 2 after 52 weeks of
ERT. Pectus carinatum in subject 3 was reportedly less pro-
nounced after 52 weeks of therapy. Clinical kyphosis was
absent at baseline but developed in subject 2 by week 26.
Macrocephaly >97th percentile was noted in subject 3 at
baseline and through week 52. Mild joint contractures, report-
ed at baseline for subjects 1 and 2, did not appear to change in
severity during the study period. Hepatosplenomegaly, which
was present at baseline in subjects 1 and 4, had normalized
after 52 weeks in subject 1 and did not worsen in subject 4. An
umbilical hernia persisted throughout the study in subject 3
and developed in subjects 2 and 4 by week 26.
Radiographic features
Table 2 summarizes the radiographic findings at baseline and
at week 52 for the four subjects. Some radiographic abnor-
malities were present in all subjects at baseline, including the
youngest subject (subject 2) who was 3.3 months of age. The
radiographic changes observed at 52 weeks reveal that
galsulfase treatment did not prevent the progression of
dysostosis multiplex in any of the subjects. The spine, pelvic
and hand films of subject 1 (Fig. 1) are illustrative of the
presentation and progression of some manifestations of
dysostosis multiplex. By 52 weeks, all subjects demonstrated
characteristic superiorly notched vertebral bodies, acetabular
hypoplasia, and/or metacarpal shortening and proximal
pointing. There was, however, radiographic improvement of
kyphosis in subject 3. Radiographically, no untoward or un-
expected changes in skeletal features attributable to galsulfase
treatment were observed.
Growth
All subjects were assessed as normal for length at baseline and
maintained normal length for the duration of the study, which
ranged from 52 to 152 weeks depending on time of enrollment
(Fig. 2a). Normal weight gain was maintained throughout the
study for subjects 2, 3 and 4 (Fig. 2b). Catch-up weight gain
was observed for subject 1, who had a screening weight below
the 3rd percentile for his age of 9 months that steadily
increased to the 10th-25th percentiles by week 52 and to the
25th–50th percentiles by study completion (Fig. 2b).
Subjects 2, 3 and 4 had normal head circumference mea-
surements at screening and growth remained within normal
range for 52 weeks and beyond. Subject 1 had head circum-
ference >97th percentile from baseline through week 52;
normal growth was attained by week 104 (head circumference
between 95th–97th percentile).
Secondary efficacy
Urinary GAG
At baseline, all four subjects had high urinary GAG levels
consistent with MPS VI disease, with an overall mean of
870 μg/mg creatinine. All subjects experienced a urinary
GAG level reduction of≈70 % by week 6; by week 52, a
mean decrease in GAG level of 75 % was achieved
(mean=220 μg/mg creatinine) (Supplementary Figure 1).
Formation of anti-rhASB antibodies did not appear to affect
reductions in urinary GAG level for any of the subjects
(Supplementary Figure 1). Urinary GAG concentrations
remained low for the three subjects who were in the study
for longer than 52 weeks.
Gross and fine motor function
Normal motor development was observed in subjects 2, 3 and
4 at baseline and throughout the study period. Motor delay
was suspected in subject 1 at baseline and subsequent visits.
Cardiac function
Diastolic left ventricular chamber dimensions and posterior
wall and septal thicknesses were within one standard deviation
of normal (Z-scores ranging from 0.0025 to 0.8925) both at
baseline and at week 52 of treatment (Supplementary Table 1).
Mean shortening fraction for the group was normal both at
baseline and at week 52. The incidence of mitral regurgitation
decreased from 3 to 2 infants; aortic regurgitation was not
identified. Neither aortic nor mitral stenosis was observed in
these subjects.
Vision and hearing
All subjects had normal funduscopic examinations. Corneal
clouding was observed at baseline for subjects 3 and 4 and
persisted through study completion. Intraocular pressure for
these two subjects was measured and found to be normal.
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Corneal clouding was not present at baseline but developed
and progressed in subjects 1 and 2.
All subjects had some hearing loss in both ears at baseline;
bilateral deafnesswas reported in subject 4. At study completion,
improvement in hearing in one ear was noted in subject 2, while
subjects 3 and 4 had demonstrated improvements in both ears.
Health resource utilization
All subjects required the use of health resources (≥1 treatment
with antibiotics, concomitant medication, hospitalization, pro-
cedure performed, outpatient visit, or ER visit) during the
study. Ear, nose, throat (ENT) and respiratory complications
Table 1 Physical characteristics of subjects 1–4 at baseline, 26 weeks and 52 weeks as reported by individual site investigators
Baseline 26 weeks 52 weeks
Subject 1 General appearance • Normal • Normal • Normal
Head, eyes, ears, nose, throat • Normal • Coryza • Normal
Respiratory • Normal • Normal • Normal
Cardiovascular • Normal • Normal • Normal
Gastrointestinal • Enlarged liver • Liver size decreased • Normal liver
• Enlarged spleen • Spleen size decreased • Normal spleen
Musculoskeletal • Kyphosis • Kyphosis • Kyphosis
• Prominent last/lowest rib • Prominent last/lowest rib • Prominent last/lowest rib
• Mild contractures elbows,
knees
• Mild contractures elbows,
knees
• Mild contractures elbows,
knees
• Mild pectus carinatum • Mild pectus carinatum • Mild pectus carinatum
Genitourinary • Right inguinal hydrocele • Hydrocele size decreased • Bilateral inguinal hernia
and right hydrocele
Subject 2 General appearance • Mild coarse facies, flat nasal bridge • Mild coarse facies • Mild coarse facies
Head, eyes, ears, nose, throat • Mild coarse facies, flat nasal bridge • Mild coarse facies • Mild coarse facies
Respiratory • Normal • Normal • Normal
Cardiovascular • Normal • Normal • Normal
Gastrointestinal • Diastasis recti • Diastasis recti • Diastasis recti
• Small umbilical hernia • Small umbilical hernia
Musculoskeletal • Mild knee flexion contracture • Mild knee flexion contracture • Mild knee flexion contracture
• Bilateral talipes equinovarus • Bilateral talipes equinovarus • Bilateral talipes equinovarus
• Mild kyphosis • Mild kyphosis
Genitourinary • Normal • Normal • Normal
Subject 3 General appearance • Mild coarse facies • Softening of facial features • Softening of facial features
Head, eyes, ears, nose, throat • Macrocephaly • Less ENT infections • Corneal clouding
• Gingival hyperplasia • Softer hair
Respiratory • Normal • Normal • Normal
Cardiovascular • Systolic murmur 1/6 • Systolic murmur 1/6 • Systolic murmur 2/6
Gastrointestinal • Mild umbilical hernia • Mild umbilical hernia • Mild umbilical hernia
Musculoskeletal • Mild kyphosis • Mild kyphosis • Pectus carinatum less pronounced
Genitourinary • Normal • Normal • Normal
Subject 4 General appearance • MPS VI phenotype • MPS VI phenotype • MPS VI phenotype
Head, eyes, ears, nose, throat • Normal • Normal • Normal
Respiratory • Normal • Normal • Normal
Cardiovascular • Normal • Normal • Normal
Gastrointestinal • Palpable liver and spleen • Palpable liver and spleen • Palpable liver and spleen
• Umbilical hernia • Umbilical hernia
Musculoskeletal • Left valgus foot • Left valgus foot • Left valgus foot
• Lumbar kyphosis • Lumbar kyphosis • Lumbar kyphosis
• Pectus excavatum • Pectus excavatum • Pectus excavatum
Genitourinary • Inguinal hernia • Normal • Normal
Table excludes reference to surgically placed PICC lines, MediPort, shunt lines, etc
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(e.g., upper respiratory tract infections, otitis media, respira-
tory distress, nasal congestion) as well as fever were the most
common problems to require medical intervention and were
typically resolved through use of antibiotics and other medi-
cations. Subject 1 was hospitalized for pneumonia during
week 3 of ERT and for respiratory distress at week 25.
Subject 3 was hospitalized for adenoid hypertrophy at week
9. Subject 4 underwent inguinal hernia repair at week 1.
Safety
No clinically significant physical findings related to safety
were observed. Only one subject (subject 4) in the 2.0 mg/
kg/week dose group had clinically significant changes in vital
signs. This subject experienced several events of pyrexia
during and after infusions that were clinically significant and
were reported as AEs.
No clinically significant abnormal laboratory values were
reported during the study. The majority of test results were
within the normal reference ranges and no systemic changes
compromised subject safety. Subject 1 had the minimum quan-
tifiable dilution factor (DF) anti-rhASB antibody titer (30 DF)
at baseline; by week 6, there were measurable (≥30 DF)
anti-rhASB antibody titers in all subjects. Subjects 2 and 3
developed total anti-rhASB antibody titers of ≥1,770,000 DF
(maximum quantifiable value) within 52 weeks of treatment
Table 2 Radiological characteristics of subjects 1–4 at baseline and at 52 weeks
Baseline 52 weeks
Subject 1 Spine • Superior notched L1 • Superior notched L1
• Gibbus • Increased gibbus
• Marked subluxation of L1 over L2
and slight T12 over L1
Pelvis • Rounded iliac wings • Rounded iliac wings
• Tapered lower ilia • Increased tapered lower ilia
• Normal acetabular roofs • Poor acetabular roof formation
Hands and wrists • Mild metacarpal shortening • Continuing mild metacarpal shortening
• No significant proximal pointing • Mild proximal pointing
• Carpal ossification delay
Subject 2 Spine • Mild superior notched L1, L2 • Mild superior notched T12
• Moderate superior notched L1, L2
Pelvis • Poor acetabular roof formation • Rounded iliac wings
• Tapered lower ilia
• Poor acetabular roof formation
Hands and wrists • Normal • Normal
Subject 3 Spine • Mild superior notched T12 • Same superior notching of T12, L1, L2
• Severe superior notched L1, L2 • Milder kyphosis
• Kyphosis
Pelvis • Rounded iliac wings • Rounded iliac wings
• Tapered lower ilia • Increased tapered iliac wings into acetabular roof
• Normal acetabular roofs • Poor acetabular roof formation
Hands and wrists • Not available • Mild metacarpal shortening
• Moderate proximal pointing
• Carpal ossification delay/small carpal centers
Subject 4 Spine • Severe superior notched L1 • Unreadable film (overlying cast)
• Moderate superior notched L2
• Hypoplastic L1 vertebral body
• Gibbus
Pelvis • Rounded iliac wings • Upper iliac wings obscured by cast
• No tapering • No tapering
• Poor acetabular roof formation • Poor acetabular roof formation
Hands and wrists • Moderate metacarpal shortening • Moderate metacarpal shortening
• Mild proximal pointing • Moderate proximal pointing
• No carpal ossification delay/normal carpal sizes • Mild carpal ossification delay/normal carpal sizes
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(Supplementary Figure 1). Subject 1, who was in the study for
longer than 52 weeks, developed total anti-rhASB antibody
titers of ≥1,770,000 DF at week 78; by study termination
these dropped to 590,490 DF. However, urinary GAG levels
remained low compared with baseline levels for all subjects.
All four subjects experienced AEs during 52 weeks of treat-
ment with galsulfase (Table 3). A total of 135 AEs were report-
ed, of which 74 were reported for the subjects in the 1.0 mg/kg/
week dose group (35 AEs for subject 1 and 39 AEs for subject
2) and 61 reported for those in the 2.0 mg/kg/week dose group
(16 AEs for subject 3 and 45 AEs for subject 4). Two subjects
experienced possible treatment-related AEs (one event of nasal
congestion in subject 2 and three events of fever for subject 4).
Two subjects experienced a severe AE that was not related to
treatment (cervical spinal stenosis in subject 1; bilateral deafness
reported at baseline in subject 4). No subject discontinued from
the study due to an AE or died during the study. Three subjects
(subjects 2, 3 and 4) experienced a total of nine AEs during an
infusion. Subject 4 had three events of fever that were consid-
ered to be possibly infusion-associated reactions (an AE that
a
b
c
Fig. 1 Radiographs of subject
1 at baseline and at 52 weeks. a
Lateral spine, baseline: superior
notched (inferiorly beaked) L1
vertebral body; significant gibbus.
Lateral spine, 52 weeks : superior
notched, hypoplastic L1;
increased gibbus; multiple
vertebral subluxations. b Pelvis,
baseline: rounded iliac wings;
tapered lower ilia (characteristic
of dysostosis multiplex). Pelvis ,
52 weeks: increased tapering of
lower ilia into acetabular roof
region; rounded iliac wings. c
Hand and wrist, baseline: mild
metacarpal shortening; no
significant proximal pointing.
Hand and wrist, 52 weeks:
continuing mild metacarpal
shortening, mild proximal
pointing; carpal ossification delay
with tiny carpal centers
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occurred during an infusion and was related to treatment with
galsulfase); none were considered serious or severe, and the rate
of subsequent infusions was not adjusted as a result of these
infusion-associated reactions. Two of these fever events were
resolved after treatment with paracetamol.
Although SAEs were more frequent in the high dose group
(five versus three SAEs), none of the SAEs were identified by
investigators as related to galsulfase infusion (Table 3). Of
these, one was assessed as severe (bilateral deafness), six were
moderate in severity (pneumonia, respiratory distress, adenoid
hypertrophy, poor venous access, scoliosis, thoracic cast), and
one was assessed as mild (inguinal hernia repair).
Discussion
The use of galsulfase therapy in MPS VI infants has not
been extensively studied. The phase 1, 2, and 3 clinical trials
did not include subjects younger than 5 years of age. Two
recent sibling study reports suggest that galsulfase admin-
istered at the 1.0 mg/kg/week dose level in infants is safe
and provides clinical benefit (Furujo et al 2011; McGill
et al 2010). Although the limited number of subjects, short
period of treatment, and absence of a control group or
matched sibling population in our study do not allow for
definitive conclusions regarding efficacy of galsulfase in
this age group, results from this study do provide further
insight into the potential benefits and limitations of early
initiation of therapy.
The primary goal of this study was to investigate the effect
of two dose levels of galsulfase on the progression of MPS VI
skeletal dysplasia as determined by dysmorphic changes, ra-
diographic changes, and growth. Our results suggest that
galsulfase therapy improves or prevents progression of facial
dysmorphism in infants, a finding that is consistent with the
two MPS VI sibling studies (Furujo et al 2011; McGill et al
Fig. 2 a Length by age relative
to age-matched percentages of
normal values.1 b Weight by age
relative to age-matched
percentages of normal values.1
1 Reference curves are 3, 5, 10,
25, 50, 75, 90, 95 and 97 percent
of normal by age
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2010). However, galsulfase treatment did not prevent the pro-
gression of dysostosis multiplex in the four subjects in this
study, although radiographic improvement of kyphosis was
observed in one subject. Similarly, dysostosis multiplex
changes continued to develop in the galsulfase-treated infants
in the MPS VI sibling studies. Despite initiation of ERT at
8 weeks and 182 weeks of treatment, the skeletal survey of the
younger Australian MPS VI sibling was reported to reveal
similar radiographic abnormalities at 3.6 years as those of her
older sibling at the same age, who was untreated at the time
(McGill et al 2010). Prevention of scoliosis in the younger sibling
was associatedwith galsulfase treatment, however. Pre- and post-
ERT spine and hand radiographs of the younger sibling of the
Japanese MPS VI sibling pair revealed progression of manifes-
tations of dysostosismultiplex despite commencement of therapy
at 6 weeks and 36 months of treatment; however, these radio-
graphic changes were comparatively milder than those of her
older sibling at the same age, suggesting that galsulfasemay have
slowed the progression of the characteristic radiographic changes
(Furujo et al 2011). In our study, randomization allocated the
lower dose level to the two youngest subjects, subjects 1 and 2,
who at baseline showed fewer radiographic abnormalities com-
pared to the older subjects. The impact of a higher dose or an
increased dosing frequency on bone pathology warrants further
investigation. The impact of neonatal intervention should also be
investigated. A newborn without radiological evidence of
dysostosis multiplex was reported to have initiated galsulfase
treatment at 5 days of age (Horovitz et al 2013); radiological
follow-up of this patient would be insightful, particularly as our
youngest subject (subject 2) already had radiographic abnormal-
ities at onset of therapy at age 3.3 months. Elucidation of the
mechanisms that cause the various bone pathologies of MPS
disease may provide additional insight into the optimal mode of
therapy.
All four subjects were able to maintain or achieve normal
growth for the duration of the study. However, it is difficult to
determine if treatment with galsulfase contributed to normal
growth (length) maintenance since MPS VI patients may
demonstrate growth acceleration with advanced bone matura-
tion during the first years of life (Heron et al 2004); a similar
growth pattern has also been reported in young children with
Morquio A syndrome (Montano et al 2008). Longer follow-up
over 5–10 years will be necessary to assess the long-term
effects of galsulfase on height. Increased height and rate of
growth in response to long-term galsulfase therapy has been
demonstrated in MPS VI patients aged 5 years and older, with
those under 16 years of age showing the greatest improve-
ments (Decker et al 2010).
Consistent with results from previous clinical studies
(Harmatz et al 2006, 2008), reductions of approximately
70 % in urinary GAG levels from baseline were observed
for all subjects (Supplementary Figure 1). These levels
approached age-normalized upper limits of normal
(Gallegos-Arreola et al 2000; Iwata et al 2000; Wood et al
2012). While urinary GAG levels decreased throughout the
study, anti-rhASB antibodies increased to levels as high
as ≥1,770,000 DF (Supplementary Figure 1). A recent study of
MPS VI patients followed for 5 years showed no correlation
between antibody titers and urinary GAG levels, including in
patients who developed titers ≥1,770,000 DF (Hendriksz et al
2013). Similar stability of urinary GAG levels in the presence
of antibody was also observed for most patients in the phase 3
clinical trial (Harmatz et al 2006).
No declines in gross or fine motor function were observed in
any of the infants, including subject 1 with suspected motor
delay.Motor development and speech delay have been reported
in MPS VI children under 5 years of age (Horovitz et al 2013).
It will require longer follow-up of the study cohort to determine
Table 3 Summary of treatment-emergent adverse events during 52 weeks of galsulfase therapy
1.0 mg/kg dose (n =2) 2.0 mg/kg dose (n =2) All subjects
(n=4)
Subject Eventa Subject Eventa Subjecta Eventa
n n n n n n
Any AEs 2 74 2 61 4 135
Study drug-related AEb 1 1 1 3 2 4
Any SAEs 2 3 2 5 4 8
Study drug-related SAEb 0 0 0 0 0 0
Withdrawal from study due to AE 0 0 0 0 0 0
Death 0 0 0 0 0 0
AEs during infusion 1 3 2 6 3 9
Study drug-related AEsb during infusion 0 0 1 3 1 3
aMultiple events were counted if a subject had the same AE with different onset dates or times
bAEs classified by the investigator as possibly or probably related to study drug
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the significance of the delay in subject 1 and the continued
normality in the other subjects. It is notable that subject 1 had to
relocate with one parent to the study site and this disruption
may have contributed to the developmental delay.
Cardiac dimensions were within one standard deviation of
normal and cardiac function was normal at both baseline and
after 52 weeks of treatment in these infants. Although mitral
regurgitation was identified in three subjects at baseline, it was
observed in only two infants after 52 weeks. None of the
subjects had aortic regurgitation, aortic stenosis or mitral
stenosis. Our findings suggest that early initiation of treatment
with galsulfase may prevent the development of ventricular
hypertrophy and the progression of even mild valve regurgi-
tation, findings that are hallmarks of MPS VI in older children
(Braunlin et al 2013). Preservation of cardiac function was
associated with early initiation of ERT in the MPS VI sibling
studies (Furujo et al 2011; McGill et al 2010). Long-term ERT
has been shown to prevent the progression of cardiac valve
abnormalities when administered before the age of 12 years
(Braunlin et al 2013).
Improvements in hearing were noted in three of our sub-
jects, including bilateral improvement in subject 4 who had
baseline bilateral deafness and was dosed at 2.0 mg/kg/week.
Early initiation of galsulfase treatment was associated with
improvement and prevention of hearing loss in the Japanese
sibling study (Furujo et al 2011). However, early initiation of
ERT was not found to be effective in preventing the progres-
sion of corneal clouding in our subjects, a finding that is
consistent with the MPS VI sibling studies (Furujo et al
2011; McGill et al 2010). The avascular nature of the cornea
likely reduces exposure of the cornea to circulating galsulfase.
Our results suggest that early initiation of galsulfase
treatment may improve or prevent progression of
hepatosplenomegaly, which is in line with findings from
the two sibling studies (Furujo et al 2011; McGill et al
2010). Reductions in liver and spleen size following
ERT have been observed in older MPS VI patients
(Harmatz et al 2005; Hendriksz et al 2013). However,
based on our study, early ERT does not appear to
prevent the development of hernias.
All four subjects required the use of health resources during
the study. Generally, health resources were used to address
MPS VI disease manifestations and to treat illnesses common
to children of the same age range of the subjects. The number
of subjects is small and the absence of a control groupmakes it
difficult to draw any conclusions about changes in health
utilization with galsulfase.
Galsulfase was safe and well tolerated in the four subjects
who participated in this study. Clinical changes were primarily
indicative of MPS VI disease and were also similar between
the two dose groups. In addition, there were no clinically
relevant abnormal changes in laboratory test results over time
for subjects in either group. One subject (subject 4) had
clinically significant changes in vital signs which consisted
of events of pyrexia that occurred during infusion and were
considered possibly related to drug; however these reactions
were not consistent with anaphylactoid–type reactions, re-
solved after three infusions and did not require any change
in rate or any pre-infusion medication. The safety profile of
the 2.0 mg/kg/week dose was not different in a clinically
meaningful manner to that of the 1.0 mg/kg/week dose. The
overall safety profile is consistent with that of previous
galsulfase clinical trials involving subjects older than 5 years
of age (Harmatz et al 2006, 2008).
No significant difference was observed in the clinical or
safety outcomes of the two dose groups, although it is
important to recognize that the groups are small. Since
the two older subjects were randomized to the high dose
group, it is possible that we did not observe a difference in
efficacy because these subjects started therapy at a signif-
icantly later age. Furthermore, the subjects in the high dose
group were diagnosed with MPS VI based on clinical
symptoms, suggesting that they could have more rapidly
progressing disease compared to the two subjects in the
low dose group who were diagnosed based on known
family history. It is unlikely that the lack of difference in
efficacy between the two doses is related to high antibody
levels since one subject in the high dose group (subject 4)
had very low antibody titers while the other subject in the
high dose group (subject 3) had similar antibody titers to
those observed for the subjects receiving the lower dose
(Supplementary Figure 1).
Further investigation of galsulfase therapy initiated early in
subjects with MPS VI, including long-term follow-up of
growth outcomes, is warranted to provide more complete
information on the potential benefits of early treatment. The
four subjects in this study are being followed to further eluci-
date long-term effects of early initiation of ERT. A Clinical
Surveillance Program sponsored by BioMarin Pharmaceutical
Inc. is currently underway to document the long-term effects
of galsulfase treatment on clinical outcomes and safety in
patients with MPS VI (Hendriksz et al 2013).
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